Clinical data and the effect of antiviral treatment on immunoglobulin heavy-chain gene rearrangement and bcl-2 translocation in patients with chronic hepatitis C virus infection
| . | Sex/Age . | Cirrhosis . | Cryoglobulin (cryocrit) . | MC-related symptoms . | ALT (IU/L) . | HCV genotype . | Treatment or follow-up*(duration) . | IgH† . | Bcl-2 translocation† . | Biochemical response . | Virologic response . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre . | Post . | Pre . | Post . | ||||||||||
| Treated group, no. | |||||||||||||
| 1 | F/47 | Yes | + (2.5%) | Yes | 112 | 1b | IFN (12 m) | + | − | − | − | No | No |
| 2 | M/40 | No | + (7.8%) | Yes | 220 | 2a | IFN (12 m) | + | − | − | − | Yes | Yes |
| 3 | M/62 | Yes | + (2.9%) | Yes | 65 | 1a | IFN (12 m) | + | + | − | − | No | No |
| 4 | F/52 | No | − | 115 | 1b | IFN (12 m) | + | − | − | − | Yes | Yes | |
| 5 | M/48 | No | + (3.5%) | No | 87 | ND | IFN (12 m) | + | − | − | − | Yes | Yes |
| 6 | F/52 | No | + (1.7%) | Yes | 51 | ND | IFN (12 m) | + | − | − | − | Yes | Yes |
| 7 | F/23 | No | + (4.7%) | Yes | 22 | 1b/2a | IFN-RBV (12 m) | + | + | − | − | No | |
| 8 | M/61 | No | + (34%) | Yes | 175 | 1b | IFN-RBV (12 m) | + | − | + | − | Yes | Yes |
| 9 | F/54 | No | + (1.2%) | No | 220 | 4 | IFN-RBV (6 m) | + | − | − | − | Yes | Yes |
| 10 | F/62 | No | + (7.2%) | Yes | 115 | ND | IFN-RBV (12 m) | − | − | + | − | Yes | Yes |
| 11 | F/51 | No | + (1.2%) | No | 74 | 2a | IFN-RBV (12 m) | − | − | + | − | Yes | Yes |
| 12 | M/42 | No | + (1.4%) | No | 55 | 1b | IFN-RBV (12 m) | − | − | + | − | Yes | Yes |
| 13 | M/58 | No | + (2.2%) | Yes | 38 | 1b | IFN-RBV (12 m) | − | − | + | − | Yes | Yes |
| 14 | M/52 | No | + (4.7%) | No | 80 | 1b | IFN-RBV (12 m) | − | − | + | − | Yes | Yes |
| 15 | F/60 | Yes | − | 80 | 2a | IFN-RBV (6 m) | − | − | + | + | No | No | |
| Untreated group, no. | |||||||||||||
| 1 | M/71 | Yes | + (1.7%) | No | 110 | 1b | 12 m | + | + | − | − | No | No |
| 2 | M/64 | No | + (1.7%) | No | 117 | ND | 12 m | + | + | − | − | No | No |
| 3 | M/65 | No | − | 15 | 1b | 12 m | + | + | − | − | No | No | |
| 4 | F/52 | No | + (1.5%) | No | 79 | 2a | 12 m | + | − | − | − | No | No |
| 5 | F/66 | Yes | + (2.2%) | No | 112 | 1b | 12 m | + | + | − | − | No | No |
| 6 | M/57 | Yes | + (3.1%) | Yes | 48 | ND | 12 m | + | + | − | + | No | No |
| 7 | M/59 | Yes | − | 161 | 1b | 12 m | + | + | − | − | No | No | |
| 8 | F/78 | Yes | + (11.4%) | Yes | 49 | 2a | 12 m | + | + | − | + | No | No |
| 9 | F/74 | Yes | + (2.6%) | No | 36 | ND | 12 m | − | − | + | + | No | No |
| 10 | F/65 | Yes | + (3.1%) | Yes | 74 | ND | 12 m | − | − | + | + | No | No |
| 11 | M/58 | Yes | + (1.3%) | No | 115 | 1b | 12 m | − | − | + | + | No | No |
| 12 | F/64 | No | − | 84 | 1b | 12 m | − | − | + | − | No | No | |
| 13 | M/61 | No | − | 49 | UD | 12 m | − | − | + | + | No | No | |
| 14 | F/72 | Yes | − | 151 | ND | 12 m | − | − | + | + | No | No | |
| . | Sex/Age . | Cirrhosis . | Cryoglobulin (cryocrit) . | MC-related symptoms . | ALT (IU/L) . | HCV genotype . | Treatment or follow-up*(duration) . | IgH† . | Bcl-2 translocation† . | Biochemical response . | Virologic response . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre . | Post . | Pre . | Post . | ||||||||||
| Treated group, no. | |||||||||||||
| 1 | F/47 | Yes | + (2.5%) | Yes | 112 | 1b | IFN (12 m) | + | − | − | − | No | No |
| 2 | M/40 | No | + (7.8%) | Yes | 220 | 2a | IFN (12 m) | + | − | − | − | Yes | Yes |
| 3 | M/62 | Yes | + (2.9%) | Yes | 65 | 1a | IFN (12 m) | + | + | − | − | No | No |
| 4 | F/52 | No | − | 115 | 1b | IFN (12 m) | + | − | − | − | Yes | Yes | |
| 5 | M/48 | No | + (3.5%) | No | 87 | ND | IFN (12 m) | + | − | − | − | Yes | Yes |
| 6 | F/52 | No | + (1.7%) | Yes | 51 | ND | IFN (12 m) | + | − | − | − | Yes | Yes |
| 7 | F/23 | No | + (4.7%) | Yes | 22 | 1b/2a | IFN-RBV (12 m) | + | + | − | − | No | |
| 8 | M/61 | No | + (34%) | Yes | 175 | 1b | IFN-RBV (12 m) | + | − | + | − | Yes | Yes |
| 9 | F/54 | No | + (1.2%) | No | 220 | 4 | IFN-RBV (6 m) | + | − | − | − | Yes | Yes |
| 10 | F/62 | No | + (7.2%) | Yes | 115 | ND | IFN-RBV (12 m) | − | − | + | − | Yes | Yes |
| 11 | F/51 | No | + (1.2%) | No | 74 | 2a | IFN-RBV (12 m) | − | − | + | − | Yes | Yes |
| 12 | M/42 | No | + (1.4%) | No | 55 | 1b | IFN-RBV (12 m) | − | − | + | − | Yes | Yes |
| 13 | M/58 | No | + (2.2%) | Yes | 38 | 1b | IFN-RBV (12 m) | − | − | + | − | Yes | Yes |
| 14 | M/52 | No | + (4.7%) | No | 80 | 1b | IFN-RBV (12 m) | − | − | + | − | Yes | Yes |
| 15 | F/60 | Yes | − | 80 | 2a | IFN-RBV (6 m) | − | − | + | + | No | No | |
| Untreated group, no. | |||||||||||||
| 1 | M/71 | Yes | + (1.7%) | No | 110 | 1b | 12 m | + | + | − | − | No | No |
| 2 | M/64 | No | + (1.7%) | No | 117 | ND | 12 m | + | + | − | − | No | No |
| 3 | M/65 | No | − | 15 | 1b | 12 m | + | + | − | − | No | No | |
| 4 | F/52 | No | + (1.5%) | No | 79 | 2a | 12 m | + | − | − | − | No | No |
| 5 | F/66 | Yes | + (2.2%) | No | 112 | 1b | 12 m | + | + | − | − | No | No |
| 6 | M/57 | Yes | + (3.1%) | Yes | 48 | ND | 12 m | + | + | − | + | No | No |
| 7 | M/59 | Yes | − | 161 | 1b | 12 m | + | + | − | − | No | No | |
| 8 | F/78 | Yes | + (11.4%) | Yes | 49 | 2a | 12 m | + | + | − | + | No | No |
| 9 | F/74 | Yes | + (2.6%) | No | 36 | ND | 12 m | − | − | + | + | No | No |
| 10 | F/65 | Yes | + (3.1%) | Yes | 74 | ND | 12 m | − | − | + | + | No | No |
| 11 | M/58 | Yes | + (1.3%) | No | 115 | 1b | 12 m | − | − | + | + | No | No |
| 12 | F/64 | No | − | 84 | 1b | 12 m | − | − | + | − | No | No | |
| 13 | M/61 | No | − | 49 | UD | 12 m | − | − | + | + | No | No | |
| 14 | F/72 | Yes | − | 151 | ND | 12 m | − | − | + | + | No | No | |
MC indicates mixed cryoglobulinemia; ALT, alanine aminotransferase; HCV, hepatitis C virus; IgH, immunoglobulin heavy-chain gene; IFN, interferon α; ND, not done; RBV, ribavirin; UD, undetermined.
Follow-up applies to untreated group.
Pre: at baseline. Post: at the end of the follow-up period (untreated patients) and at the end of treatment (in treated patients). Note that one patient from the treated group (no. 8) was positive for both monoclonal IgH rearrangement and t(14;18) translocation.